中東およびアフリカの蛍光 in situ ハイブリダイゼーション (FISH) 市場
Market Size in USD Billion
CAGR :
% 
 予測期間 |
2024 –2030 |
 市場規模（基準年） |
|
 Market Size (Forecast Year) |
USD 50.93 |
 CAGR |
% |
| 主要市場プレーヤー |
中東およびアフリカの蛍光 in situ ハイブリダイゼーション (FISH) 市場、製品タイプ別 (消耗品、機器、ソフトウェア)、テクノロジー別 (DNA 蛍光 in situ ハイブリダイゼーション、RNA 蛍光 in situ ハイブリダイゼーション、PNA 蛍光 in situ ハイブリダイゼーション、その他)、アプリケーション別 (がん研究、遺伝子研究、感染症、個別化医療、その他)、使用法別 (臨床、研究、コンパニオン診断)、エンドユーザー別 (病院および診療所、診断研究所、製薬およびバイオテクノロジー企業、契約研究機関、学術および研究機関、その他)、流通チャネル別 (小売販売、直接入札、オンライン販売、その他) - 2030 年までの業界動向および予測。
中東およびアフリカの蛍光 in situ ハイブリダイゼーション (FISH) 市場分析と洞察
がんや遺伝性疾患に関する一般の認識の高まりにより、市場の需要が高まっています。主要な市場プレーヤーは、この重要な時期にさまざまな製品の発売と承認に注力しています。さらに、FISH の改良された高度な手順の増加も、市場の需要の高まりに貢献しています。
中東およびアフリカの蛍光in situハイブリダイゼーション（FISH）市場は、がんやその他の慢性疾患の増加により、2023年から2030年の予測期間に成長すると予想されています。政府やその他の機関による研究活動への多額の資金提供も、市場の成長を牽引すると予想されています。これに伴い、メーカーは市場に新製品を投入するための研究開発活動に取り組んでいます。ただし、治療手順におけるFISH技術の高コストは、市場の成長を抑制すると予想されます。特定のバイオマーカーとさまざまなプローブの需要の増加は、治療を強化するための市場成長の機会を提供すると予想されます。遺伝性疾患に対するより質の高いヘルスケアの需要の高まりと、個別化医療の採用の増加は、市場の成長を後押しすると予想されます。ただし、FISH技術に関連する倫理的な懸念と、熟練した認定専門家の不足は、市場の成長に課題をもたらすと予想されます。
Data Bridge Market Research は、中東およびアフリカの蛍光 in situ ハイブリダイゼーション (FISH) 市場は、予測期間中に 5.0% の CAGR で成長し、2030 年までに 5,093 万米ドルに達すると予測しています。乳がんや遺伝性疾患の患者数が増加しているため、製品タイプ セグメントが市場で最大のセグメントを占めています。この市場レポートでは、価格分析、特許分析、技術進歩についても詳細に取り上げています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2023年から2030年 |
|
基準年 |
2022 |
|
歴史的な年 |
2021（2015～2020年にカスタマイズ可能） |
|
定量単位 |
収益は百万米ドル、価格は米ドル |
|
対象セグメント |
製品タイプ別（消耗品、機器、ソフトウェア）、技術別（DNA蛍光in situハイブリダイゼーション、RNA蛍光in situハイブリダイゼーション、PNA蛍光in situハイブリダイゼーション、その他）、用途別（がん研究、遺伝子研究、感染症、個別化医療、その他）、使用法別（臨床、研究、コンパニオン診断）、エンドユーザー別（病院・診療所、診断研究所、製薬・バイオテクノロジー企業、契約研究機関、学術・研究機関、その他）、流通チャネル別（小売販売、直接入札、オンライン販売、その他） |
|
対象国 |
南アフリカ、サウジアラビア、バーレーン、UAE、クウェート、オマーン、カタール、エジプト、その他の中東およびアフリカ諸国 |
|
対象となる市場プレーヤー |
Thermo Fisher Scientific Inc.、Bio-Techne、Abbott、Agilent Technologies、Merck KGaA、F. Hoffmann-La Roche Ltd、Abnova Corporation、BioDot、Biocare Medical、LLC、Abcam plc、Sysmex Asia Pacific Pte Ltd（Sysmex Corporationの子会社）、BIOZOL Diagnostics Vertrieb GmbH、Zytomed Systems GmbH、Genemed Biotechnologies、Inc.、Bio SB、BioGenex、Excilone、MetaSystems、Kaneka Eurogentec SA、BioCat GmbH、Leica Biosystems Nussloch GmbHなど |
市場の定義
蛍光 in situ ハイブリダイゼーション (FISH) と呼ばれる分子細胞遺伝学的手法により、細胞内の特定の DNA 配列または染色体全体の位置を特定できます。この手法は、遺伝性疾患の診断、遺伝子のマッピング、染色体異常の特定に使用され、また、関連種の異なる染色体上の遺伝子がどのように構成されているかを比較するためにも使用できます。FISH を実行すると、二重らせん構造がほどかれ、蛍光分子に接続されたすべてのプローブが、蛍光顕微鏡で確認できるサンプル DNA の特定の配列に結合されます。
FISH は、腫瘍学、予防および生殖医療、ゲノムおよび細胞生物学研究の診断目的で頻繁に使用されています。これは、感染症や染色体異常を発見するための業界で認められた方法です。ただし、FISH 製品およびプローブの承認に関する厳格な規制と基準により、市場の成長が抑制されると予想されます。
中東およびアフリカの蛍光 in situ ハイブリダイゼーション (FISH) 市場の動向
このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。
ドライバー
- 遺伝性疾患とがんの負担が増大
遺伝子異常は全体としてはまれですが、個々の病気としては非常に頻繁に発生します。遺伝子の変化はすべてのがんの原因です。がんのわずか 5% から 10% が遺伝的に素因があります。それでも、同じ種類のがんが家族内で発生する場合、遺伝ががんの原因であるように見えることがあります。血液がんと固形がんはどちらも、さまざまな遺伝子異常を伴う異質な疾患です。過去 20 年間に実施されたゲノム不安定性と疾患発症の関係に関する広範な調査の結果として、染色体断片の増加、喪失、または再配置や遺伝子変異などのゲノム異常が増加しており、さまざまな悪性腫瘍の発症の原動力となっています。欠失、重複、転座などのさまざまな染色体異常の臨床診断は、FISH やその他の in situ ハイブリダイゼーション技術に依存しており、これが市場の成長を牽引しています。
- FISH製品の革新と進歩
特定の DNA 配列を見つけ、遺伝性疾患を診断し、遺伝子をマッピングし、さまざまな癌を引き起こす新しい癌遺伝子または遺伝子異常を発見するための最も信頼性の高い方法は FISH です。最近の技術の進歩により、比較ゲノムハイブリダイゼーションやマルチカラー全染色体プローブを使用したマルチプレックス FISH などのアレイベースの方法を使用して、ゲノム全体を同時にスクリーニングすることが可能になりました。遺伝性疾患との戦いにおいて、FISH は細胞遺伝学の分野を根本的に変革し、現在では市場の成長を促進する信頼できる診断および研究ツールとして認められています。
拘束
- FISH検査の高コスト
FISH として知られる高分子認識技術は、DNA または DNA/RNA 二重鎖の相補性に依存しています。FISH テストは、特定の遺伝子または遺伝子セグメントを含む、人間の細胞に存在する遺伝物質を「マッピング」します。FISH テストは、病気に関連する遺伝子異常を見つけることができるため、一部の種類の癌の診断に役立ちます。コストの問題は、現代の分子診断ラボにとって最も重要な問題です。ラボが増加するテスト量とスループットを処理できるようになるだけでなく、複雑な分子アッセイの自動化により、市場の成長を抑制する試薬費用の観点からテストのコストが大幅に削減されます。
機会
- 遺伝子異常の早期発見に関する国民の意識の高まり
遺伝子検査は、遺伝性疾患の予防、治療、早期発見において患者が重要な決定を下すのに役立ちます。遺伝子検査の重要性に対する認識が低いことが、遺伝性疾患の発生率の増加につながっています。
遺伝性疾患は、通常 DNA の変異、または染色体の数や全体的な構造の変化によって引き起こされる、人に受け継がれる健康状態です。よく知られているいくつかの種類の疾患は、遺伝性遺伝子変異に関連していることが判明しています。
今後、FISH 技術を使用した遺伝性疾患の早期検出に関する認識が高まることで、遺伝性疾患の診断、遺伝子マッピング、さまざまな種類の癌や遺伝性疾患に寄与する新しい癌遺伝子や遺伝子異常の特定に役立ち、市場成長の機会が生まれます。
チャレンジ
- FISHプローブの承認に関する厳格な政府規制
高齢化人口の増加と、早期診断と適切な治療で予防可能な慢性疾患の増加に伴い、世界中で FISH 技術の使用が急速に増加しています。同時に、市場で FISH 技術を扱う企業は、地域で製品を発売するために上級当局から承認を得るために、一定の規制に従う必要があります。これらの厳格なガイドラインに従う必要があり、これはすべてのステップの中で最も困難な作業の 1 つです。さまざまな医療機器の市販前承認は、国によって異なります。
COVID-19後の中東・アフリカ蛍光in situハイブリダイゼーション（FISH）市場への影響
パンデミックは、FISHメーカーとユーザーに悪影響を及ぼしています。市場はCOVID-19の影響を大きく受けており、FISHを利用した研究が増加しています。2022年11月にPLOS One Journalに掲載されたそのような研究の1つでは、唾液中のSARS-CoV-2を検出するためにFISHベースの方法を採用しました。この方法では、SARS-CoV-2に固有のCy3標識DNAプローブを使用し、概念実証として蛍光顕微鏡を使用して手動で分析を行いました。
メーカーは、COVID-19後の回復に向けてさまざまな戦略的決定を下しています。各社は、FISH市場に関わる技術とテスト結果を改善するために、複数の研究開発活動、製品の発売、戦略的パートナーシップを行っています。
最近の動向
- 2023年3月、アブカム社はCiteAbの権威ある年間業界賞で「抗体サプライヤー・オブ・ザ・イヤー」を受賞したことを発表しました。これは、Fast Companyが最近、データの再現性を高めるための画期的な取り組みにより、アブカム社を世界で最も革新的な企業の1つに挙げたことに続くものです。2022年に抗体製品の引用が最も多かったプロバイダーが、CiteAbの「抗体サプライヤー・オブ・ザ・イヤー」の栄誉を受けます。さらに、アブカム社は「翻訳後修飾抗体サプライヤー・オブ・ザ・イヤー」のカテゴリーで「高く評価」され、これらの困難なターゲットに対する抗体の作成と検証の難しさが認められました。これにより、同社は中東およびアフリカ規模で知られるようになりました。
- 2023年3月、BIOZOL Diagnostics Vertrieb GmbHはAlphaScience GmbHの買収を発表しました。この買収により、BIOZOL Diagnostics Vertrieb GmbHは中東およびアフリカの研究および診断市場における優位な地位を強化しました。多数の新しいサプライヤーとのつながり、優れた製品知識、技術的によく訓練されたスタッフにより、AlphaScienceはBIOZOLを強化します。2つの組織間の大きな相乗効果により、顧客とサプライヤーへの提供が向上します。
- 2022年7月、バイオテクネは、中咽頭扁平上皮がん（OPSCC）の患者が高リスクヒトパピローマウイルス（HPV）を特定できるようにするために、CE-IVD指定のRNAscope ISHプローブ高リスクHPVをヨーロッパで発売すると発表しました。FFPE組織サンプル中のHPV E6 / E7 mRNAの定性的な識別には、RNAscope ISHプローブ高リスクHPVが使用されます。これにより、世界中でより良いソリューションを提供するビジネスが促進されました。
中東およびアフリカの蛍光in situハイブリダイゼーション（FISH）市場の範囲
中東およびアフリカの蛍光 in situ ハイブリダイゼーション (FISH) 市場は、製品タイプ、テクノロジー、アプリケーション、使用法、エンド ユーザー、流通チャネルに基づいて、6 つの主要なセグメントに分割されています。セグメント間の成長は、ニッチな成長分野と市場にアプローチするための戦略を分析し、コアアプリケーション領域とターゲット市場の違いを判断するのに役立ちます。
製品タイプ別
- 消耗品
- 楽器
- ソフトウェア
製品タイプに基づいて、市場は消耗品、機器、ソフトウェアに分類されます。
テクノロジー
- DNA蛍光in situハイブリダイゼーション
- RNA蛍光in situハイブリダイゼーション
- PNA蛍光in situハイブリダイゼーション
- その他
技術に基づいて、市場は DNA 蛍光 in situ ハイブリダイゼーション、RNA 蛍光 in situ ハイブリダイゼーション、PNA 蛍光 in situ ハイブリダイゼーション、その他に分類されます。
アプリケーション別
- がん研究
- 遺伝子研究
- 感染症
- パーソナライズ医療
- 他の
アプリケーションに基づいて、市場は癌研究、遺伝子研究、感染症、個別化医療、その他に分類されます。
用途別
- 臨床
- 研究
- コンパニオン診断
用途に基づいて、市場は臨床、研究、コンパニオン診断に分類されます。
エンドユーザーによる
- 病院とクリニック
- 診断検査室
- 製薬・バイオテクノロジー企業
- 委託研究機関
- 学術・研究機関
- その他
エンドユーザーに基づいて、市場は病院と診療所、診断研究所、製薬およびバイオテクノロジー企業、契約研究機関、学術研究機関、その他に分類されます。
流通チャネル別
- 小売販売
- 直接入札
- オンライン販売
- その他
流通チャネルに基づいて、市場は直接入札、小売販売、オンライン販売、その他に分類されます。
中東およびアフリカの蛍光 in situ ハイブリダイゼーション (FISH) 市場の地域分析/洞察
中東およびアフリカの蛍光 in situ ハイブリダイゼーション (FISH) 市場が分析され、製品タイプ、テクノロジー、アプリケーション、使用法、エンドユーザー、流通チャネルに基づいて市場規模の情報が提供されます。
この市場レポートで取り上げられている国は、南アフリカ、サウジアラビア、バーレーン、UAE、クウェート、オマーン、カタール、エジプト、およびその他の中東およびアフリカ諸国です。
南アフリカは、FISH 技術による乳がんおよび感染症治療の研究開発への投資の増加により、中東およびアフリカ地域を支配すると予想されています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、中東およびアフリカのブランドの存在と入手可能性、地元および国内ブランドとの競争が激しいか少ないために直面する課題、販売チャネルの影響を考慮しながら、国別データの予測分析を提供します。
競争環境と中東およびアフリカの蛍光 in situ ハイブリダイゼーション (FISH) 市場シェア分析
中東およびアフリカの蛍光 in situ ハイブリダイゼーション (FISH) 市場の競争状況は、競合他社の詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と幅、アプリケーションの優位性、および技術ライフライン曲線が含まれます。上記のデータ ポイントは、会社の市場への重点にのみ関連しています。
中東およびアフリカの蛍光 in situ ハイブリダイゼーション (FISH) 市場で活動している主要な市場プレーヤーには、Thermo Fisher Scientific Inc.、Bio-Techne、Abbott、Agilent Technologies, Inc.、Merck KGaA、F. Hoffmann-La Roche Ltd、Abnova Corporation、BioDot、Biocare Medical, LLC、Abcam plc.、Sysmex Asia Pacific Pte Ltd (Sysmex Corporation の子会社)、BIOZOL Diagnostics Vertrieb GmbH、Zytomed Systems GmbH、Genemed Biotechnologies, Inc.、Bio SB、BioGenex、Excilone、MetaSystems、Kaneka Eurogentec SA、BioCat GmbH、Leica Biosystems Nussloch GmbH などがあります。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 INDUSTRY INSIGHTS
4.4 CONCLUSION
5 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER
6.1.2 INNOVATION AND ADVANCEMENTS IN FISH PRODUCTS
6.1.3 HIGH FUNDING FOR RESEARCH ACTIVITIES
6.1.4 RISING DEMAND AND USAGE OF FISH TECHNIQUES
6.2 RESTRAINTS
6.2.1 HIGH COST OF FISH TESTING
6.2.2 LIMITED AVAILABILITY OF SKILLED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 RISING PUBLIC AWARENESS ABOUT THE EARLY DETECTION OF GENETIC ABNORMALITIES
6.3.2 RISE IN DEVELOPMENT OF SPECIFIC BIOMARKERS AND VARIOUS PROBES
6.4 CHALLENGES
6.4.1 STRINGENT GOVERNMENT REGULATIONS FOR THE APPROVAL OF FISH PROBES
6.4.2 ETHICAL CONCERNS ASSOCIATED WITH FISH TECHNOLOGY
7 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 CONSUMABLES
7.2.1 FISH PROBE
7.2.1.1 FISH PROBE, BY PROBE TYPE
7.2.1.1.1 CHROMOSOME FISH PROBE
7.2.1.1.2 SPLIT FISH PROBES
7.2.1.1.3 TRANSLOCATION FISH PROBES
7.2.1.1.4 SUBTELOMERE FISH PROBES
7.2.1.1.5 PRENATAL FISH PROBES
7.2.1.1.6 OTHERS PROBES
7.2.1.2 FISH PROBE, BY TECHNOLOGY
7.2.1.2.1 FLOW FLUORESCENT IN SITU HYBRIDIZATION
7.2.1.2.2 C-ISH
7.2.1.2.3 D-ISH
7.2.1.2.4 Q- FLUORESCENT IN SITU HYBRIDIZATION
7.2.1.2.5 OTHERS
7.2.1.3 FISH PROBE, BY TYPE
7.2.1.3.1 RNA
7.2.1.3.1.1 MRNA
7.2.1.3.1.2 MIRNA
7.2.1.3.1.3 OTHERS
7.2.1.3.2 DNA
7.2.2 ACCESSORY KITS & REAGENTS
7.2.2.1 KITS
7.2.2.2 BUFFER
7.2.2.3 DYES
7.2.2.4 OTHERS
7.3 INSTRUMENT
7.3.1 STANDALONE
7.3.2 PORTABLE
7.3.3 HANDHELD
7.4 SOFTWARE
8 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 RNA FLUORESCENT IN SITU HYBRIDIZATION
8.3 DNA FLUORESCENT IN SITU HYBRIDIZATION
8.4 PNA FLUORESCENT IN SITU HYBRIDIZATION
8.5 OTHERS
9 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 CANCER RESEARCH
9.2.1 CANCER RESEARCH, BY CANCER TYPE
9.2.1.1 NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS)
9.2.1.1.1 BREAST CANCER
9.2.1.1.2 LUNG CANCER
9.2.1.1.3 MELANOMA
9.2.1.1.4 PROSTRATE CANCER
9.2.1.1.5 OVARIAN CANCER
9.2.1.1.6 OTHERS
9.2.1.2 HEMATOPOETIC MALIGNANCIES
9.2.1.2.1 LEUKEMIA
9.2.1.2.2 MULTIPLE MYELOMA
9.2.1.2.3 MYELODYSPLASTIC SYNDROMES (MDS)
9.2.2 CANCER RESEARCH, BY PRODUCT
9.2.2.1 CONSUMABLES
9.2.2.2 INSTRUMENTS
9.2.2.3 SOFTWARE
9.3 GENETIC RESEARCH
9.3.1 CYTOGENETICS
9.3.2 CHROMOSOMAL ABNORMALITIES
9.3.3 OTHERS
9.4 INFECTIOUS DISEASE
9.4.1 CONSUMABLES
9.4.2 INSTRUMENTS
9.4.3 SOFTWARE
9.5 PERSONALIZED MEDICINE
9.6 OTHERS
10 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE
10.1 OVERVIEW
10.2 RESEARCH
10.2.1 INSTRUMENTS
10.2.2 CONSUMABLES
10.2.3 SOFTWARE
10.3 CLINICAL
10.3.1 CONSUMABLES
10.3.2 INSTRUMENT
10.3.3 SOFTWARE
10.4 COMPANION DIAGNOSTIC
10.4.1 CONSUMABLES
10.4.2 INSTRUMENT
10.4.3 SOFTWARE
11 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER
11.1 OVERVIEW
11.2 DIAGNOSTIC LABORATORIES
11.3 HOSPITALS & CLINICS
11.4 PHARMACEUTICALS & BIOTECHNOLOGICAL COMPANIES
11.5 ACADEMIC & RESEARCH INSTITUTES
11.6 CONTRACT RESEARCH ORGANIZATIONS
11.7 OTHERS
12 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 RETAIL SALES
12.3 ONLINE SALES
12.4 DIRECT TENDER
12.5 OTHERS
13 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SOUTH AFRICA
13.1.2 SAUDI ARABIA
13.1.3 EGYPT
13.1.4 UAE
13.1.5 KUWAIT
13.1.6 QATAR
13.1.7 OMAN
13.1.8 BAHRAIN
13.1.9 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 MERCK KGAA
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 ABBOTT
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 AGILENT TECHNOLOGIES, INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 F. HOFFMANN-LA ROCHE LTD.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 THERMO FISCHER SCIENTIFIC INC.
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 ABCAM PLC.
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 COMPANY SHARE ANALYSIS
16.6.4 PRODUCT PORTFOLIO
16.6.5 RECENT DEVELOPMENTS
16.7 ABNOVA CORPORATION
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 BIO SB
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 BIOCARE MEDICAL, LLC
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 BIOCAT GMBH
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 BIODOT
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 BIOGENEX
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 BIO-TECHNE
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 COMPANY SHARE ANALYSIS
16.13.4 PRODUCT PORTFOLIO
16.13.5 RECENT DEVELOPMENT
16.14 BIOZOL DIAGNOSTICS VERTRIEB GMBH
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 EXCILONE
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 GENEMED BIOTECHNOLOGIES, INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 KANEKA EUROGENTEC S.A.
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
16.18 LEICA BIOSYSTEMS NUSSLOCH GMBH
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 METASYSTEMS
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 SYSMEX ASIA PACIFIC PTE LTD (A SUBSIDIARY OF SYSMEX CORPORATION)
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENT
16.21 ZYTOMED SYSTEMS GMBH
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
表のリスト
TABLE 1 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA INSTRUMENT IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA SOFTWARE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA RNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA DNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA PNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA HEMATOPOETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA PERSONALIZED MEDICINE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA DIAGNOSTIC LABORATORIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA HOSPITALS & CLINICS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA PHARMACEUTICAL & BIOTECHNOLOGICAL COMPANIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA ACADEMIC & RESEARCH INSTITUTES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA CONTRACT RESEARCH ORGANIZATIONS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA RETAIL SALES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA ONLINE SALES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA DIRECT TENDER IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 63 MIDDLE EAST AND AFRICA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 67 MIDDLE EAST AND AFRICA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 71 SOUTH AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 SOUTH AFRICA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 SOUTH AFRICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 74 SOUTH AFRICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 75 SOUTH AFRICA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 76 SOUTH AFRICA RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 77 SOUTH AFRICA ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 78 SOUTH AFRICA INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 SOUTH AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 80 SOUTH AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 81 SOUTH AFRICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 82 SOUTH AFRICA NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 83 SOUTH AFRICA HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 84 SOUTH AFRICA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 SOUTH AFRICA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 86 SOUTH AFRICA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 87 SOUTH AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 88 SOUTH AFRICA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 89 SOUTH AFRICA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 90 SOUTH AFRICA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 91 SOUTH AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 92 SOUTH AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 93 SAUDI ARABIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 94 SAUDI ARABIA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 SAUDI ARABIA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 96 SAUDI ARABIA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 97 SAUDI ARABIA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 98 SAUDI ARABIA RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 99 SAUDI ARABIA ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 100 SAUDI ARABIA INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 101 SAUDI ARABIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 102 SAUDI ARABIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 103 SAUDI ARABIA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 104 SAUDI ARABIA NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 105 SAUDI ARABIA HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 106 SAUDI ARABIA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 107 SAUDI ARABIA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 SAUDI ARABIA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 SAUDI ARABIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 110 SAUDI ARABIA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 111 SAUDI ARABIA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 112 SAUDI ARABIA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 113 SAUDI ARABIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 114 SAUDI ARABIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 115 EGYPT FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 116 EGYPT CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 117 EGYPT FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 118 EGYPT FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 119 EGYPT FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 120 EGYPT RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 121 EGYPT ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 122 EGYPT INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 123 EGYPT FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 124 EGYPT FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 125 EGYPT CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 126 EGYPT NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 127 EGYPT HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 128 EGYPT CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 129 EGYPT GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 130 EGYPT INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 131 EGYPT FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 132 EGYPT RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 133 EGYPT CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 134 EGYPT COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 135 EGYPT FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 136 EGYPT FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 137 U.A.E FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 138 U.A.E CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 139 U.A.E FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 140 U.A.E FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 141 U.A.E FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 142 U.A.E RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 143 U.A.E ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 144 U.A.E INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 145 U.A.E FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 146 U.A.E FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 147 U.A.E CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 148 U.A.E NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 149 U.A.E HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 150 U.A.E CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 151 U.A.E GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 152 U.A.E INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 153 U.A.E FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 154 U.A.E RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 155 U.A.E CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 156 U.A.E COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 157 U.A.E FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 158 U.A.E FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 159 KUWAIT FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 160 KUWAIT CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 161 KUWAIT FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 162 KUWAIT FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 163 KUWAIT FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 164 KUWAIT RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 165 KUWAIT ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 166 KUWAIT INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 167 KUWAIT FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 168 KUWAIT FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 169 KUWAIT CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 170 KUWAIT NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 171 KUWAIT HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 172 KUWAIT CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 173 KUWAIT GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 174 KUWAIT INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 175 KUWAIT FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 176 KUWAIT RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 177 KUWAIT CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 178 KUWAIT COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 179 KUWAIT FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 180 KUWAIT FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 181 QATAR FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 182 QATAR CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 183 QATAR FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 184 QATAR FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 185 QATAR FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 186 QATAR RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 187 QATAR ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 188 QATAR INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 189 QATAR FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 190 QATAR FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 191 QATAR CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 192 QATAR NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 193 QATAR HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 194 QATAR CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 195 QATAR GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 196 QATAR INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 197 QATAR FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 198 QATAR RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 199 QATAR CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 200 QATAR COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 201 QATAR FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 202 QATAR FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 203 OMAN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 204 OMAN CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 205 OMAN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 206 OMAN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 207 OMAN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 208 OMAN RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 209 OMAN ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 210 OMAN INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 211 OMAN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 212 OMAN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 213 OMAN CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 214 OMAN NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 215 OMAN HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 216 OMAN CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 217 OMAN GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 218 OMAN INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 219 OMAN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 220 OMAN RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 221 OMAN CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 222 OMAN COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 223 OMAN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 224 OMAN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 225 BAHRAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 226 BAHRAIN CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 227 BAHRAIN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 228 BAHRAIN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 229 BAHRAIN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 230 BAHRAIN RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 231 BAHRAIN ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 232 BAHRAIN INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 233 BAHRAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 234 BAHRAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 235 BAHRAIN CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 236 BAHRAIN NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 237 BAHRAIN HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 238 BAHRAIN CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 239 BAHRAIN GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 240 BAHRAIN INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 241 BAHRAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 242 BAHRAIN RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 243 BAHRAIN CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 244 BAHRAIN COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 245 BAHRAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 246 BAHRAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 247 REST OF MIDDLE EAST AND AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
図表一覧
FIGURE 1 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SEGMENTATION
FIGURE 11 THE GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER AND HIGH FUNDING FOR RESEARCH ACTIVITIES IS EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET FROM 2023 TO 2030
FIGURE 12 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET
FIGURE 14 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, 2022
FIGURE 19 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 20 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 21 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 22 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, 2022
FIGURE 23 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 24 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 25 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, 2022
FIGURE 27 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, 2023-2030 (USD MILLION)
FIGURE 28 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, CAGR (2023-2030)
FIGURE 29 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, LIFELINE CURVE
FIGURE 30 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, 2022
FIGURE 31 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 32 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 35 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 36 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 37 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 MIDDLE EAST AND AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SNAPSHOT (2022)
FIGURE 39 MIDDLE EAST AND AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2022)
FIGURE 40 MIDDLE EAST AND AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 MIDDLE EAST AND AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 MIDDLE EAST AND AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: PRODUCT TYPE (2023-2030)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
